TBI and Cognitive Recovery: How Pharmacy Lien Supported a Complex Brain Injury Case

James Wong — Founder & Pharmacist, LienScripts | February 14, 2026 | 9 min read

A 45-year-old professional suffered a moderate traumatic brain injury after being struck by a drunk driver. With no health insurance and a fragile cognitive recovery ahead, a pharmacy lien program covered 18 months of complex neurological medications — and the resulting documentation helped support a seven-figure settlement.

TBI and Cognitive Recovery: How Pharmacy Lien Supported a Complex Brain Injury Case

Note: This is a fictionalized case study based on composite facts. Names and identifying details are not real. The clinical details represent typical medication patterns for this injury type.

Traumatic brain injury cases are among the most medically complex and legally demanding cases in personal injury law. Unlike a fracture or a herniated disc — injuries that show up clearly on imaging — the cognitive deficits that follow a moderate TBI can be subtle, intermittent, and devastating to a patient's professional and personal life. When the neurology is complex, the medication record becomes one of the most powerful tools an attorney has to document the injury's real-world impact. This case study traces how an 18-month pharmacy lien program helped build the clinical record that supported a seven-figure settlement for a moderate TBI patient.

[!KEY] In TBI cases, a multi-drug cognitive medication regimen — documented month by month — provides objective, continuous evidence of neurological injury that neuropsychological test scores alone cannot supply.

Case Background

Patient: Marcus R. (name changed), 45-year-old male, senior project manager at a construction firm Incident: Marcus was driving home from a client meeting on a Friday evening when his vehicle was struck head-on by a drunk driver who crossed the center line on a two-lane state highway. The other driver's BAC was 0.21 at the scene. Initial Medical Response: Marcus was transported by ambulance to a Level II trauma center. At the scene, his Glasgow Coma Scale (GCS) score was 12 — within the moderate TBI range. He had a documented loss of consciousness of approximately 20 minutes and post-traumatic amnesia lasting several days. Imaging: CT head showed a small bifrontal contusion. MRI at 6 weeks post-injury revealed subtle diffuse axonal injury signal on susceptibility-weighted imaging. Insurance Situation: Marcus had recently left his employer to start his own consulting business. He had not yet enrolled in individual health coverage — he was between policies at the time of the accident. He had no health insurance at the time of injury and no disability insurance. Attorney: Christine V. (name changed), a senior partner at a plaintiff PI firm specializing in serious injury cases.

Injuries and Initial Prognosis

The bifrontal contusion and diffuse axonal injury pattern told the neurologist a clear story: the prefrontal cortex — the brain region governing executive function, attention, working memory, and emotional regulation — had absorbed the brunt of the injury. Marcus's presenting cognitive deficits were consistent with that anatomy:

• Difficulty sustaining attention for more than 20-30 minutes
• Significant working memory impairment (forgetting multi-step instructions)
• Word-finding difficulties during meetings and calls
• Emotional dysregulation (irritability, low frustration tolerance)
• Post-traumatic headaches, occurring 4-5 days per week
• Severe sleep disruption with difficulty initiating and maintaining sleep
• Depressed mood, consistent with post-TBI depression

Marcus's neuropsychologist performed baseline testing at 8 weeks post-injury. His scores on processing speed, working memory, and executive function subtests were at or below the 15th percentile — a significant drop from what would be expected for an educated professional in his field. The neuropsychologist estimated that these deficits were consistent with moderate TBI and that full recovery was uncertain, with significant risk of permanent impairment.

Medication Timeline

Because Marcus had no health insurance, his treating neurologist referred him to LienScripts within the first month after discharge. The pharmacy lien program covered all prescriptions throughout the case with no out-of-pocket cost to Marcus. The medication protocol evolved over 18 months:

Phase 1: Months 1-3 — Stabilization and Activation

Amantadine 100mg twice daily was initiated as the first cognitive agent. Originally developed as an antiviral, amantadine's dopaminergic and glutamatergic mechanisms have been studied in TBI rehabilitation for cognitive activation — particularly improving arousal, attention, and behavioral regulation in the early post-injury period. Marcus's neurologist noted meaningful improvement in morning alertness and initiation by week 6.

Gabapentin 300mg three times daily was started to address the post-traumatic headaches. Marcus's headaches had the profile of post-traumatic migraine variants — pressure, photophobia, nausea — and responded partially to gabapentin at this dose.

Sertraline 50mg daily was prescribed for the post-TBI depression and emotional dysregulation. Post-TBI depression is not simply sadness — it reflects the neurochemical disruption of injury and significantly impairs rehabilitation effort when untreated.

Zolpidem 5mg nightly (short-term) was used for the first 8 weeks only, to address the severe sleep-onset insomnia. The treating physician documented the rationale for short-term use and the plan to taper.

Phase 2: Months 4-9 — Cognitive Optimization

By month 4, amantadine had helped with arousal but Marcus continued to struggle profoundly with attention and executive function — the deficits most relevant to his professional work. His neurologist added methylphenidate 10mg twice daily, an agent with the strongest evidence base for attention and executive function recovery after TBI. The clinical documentation noted that the decision was made after reassessment showed insufficient functional improvement for Marcus to return to work responsibilities.

[!KEY] Methylphenidate for TBI attention deficits is not a casual off-label prescription — it reflects a neurologist's clinical judgment that the patient's dopaminergic attentional systems are not recovering spontaneously and require pharmacological support. This documented clinical reasoning is critical for countering defense arguments that the medication was "unnecessary."

At month 6, sertraline was increased to 75mg after Marcus reported continued mood instability and the neuropsychologist noted persistent processing speed deficits. The dose increase was documented with clinical rationale — not a reflexive escalation.

Memantine 10mg daily was added at month 7. Memantine's mechanism — NMDA receptor antagonism — targets the glutamate excitotoxicity pathway implicated in TBI neuroplasticity and secondary injury. Its use in moderate TBI cognitive recovery is off-label but reflects a growing evidence base, and Marcus's neurologist documented the clinical reasoning in full. The pharmacy records captured this addition, creating a permanent record of escalating pharmacological complexity correlated with ongoing functional impairment.

Phase 3: Months 10-18 — Long-Term Management and Documentation

By month 10, Marcus remained on the full cognitive regimen: amantadine, methylphenidate, memantine, sertraline (now at 100mg), and gabapentin. The zolpidem had been successfully tapered at month 3. The pharmacy lien record documented 15 consecutive months of active multi-drug cognitive management — an objective timeline that no defense narrative could erase.

At month 14, his neuropsychologist repeated formal neuropsychological testing. Processing speed and working memory remained below the 25th percentile. Executive function had improved to the 30th percentile — meaningful progress, but far from his estimated pre-injury baseline. The neuropsychologist's report explicitly correlated the cognitive test scores with the medication record, noting that the ongoing need for four concurrent cognitive agents was consistent with a moderate TBI that had not achieved full neurological recovery.

Marcus attempted a supervised return to modified work at month 12. The attempt failed — he could not sustain the cognitive demands of project management, could not reliably track multi-stakeholder communications, and reported significant fatigue after 3-hour work sessions. The failure was documented in medical records and corroborated by his employer.

Documentation Value

The 18-month pharmacy lien record created several distinct evidentiary assets:

Continuity of Care. Every prescription, every refill, every dose adjustment was captured in a single organized record. Defense counsel could not argue gaps in treatment or suggest that Marcus had stopped caring for his injury.

Clinical Complexity as Objective Evidence. A patient on a four-drug cognitive regimen — amantadine, methylphenidate, memantine, and sertraline — for 15 months presents an undeniable picture of sustained neurological injury. These are not medications prescribed lightly or continued without clinical reason.

Neuropsychological Corroboration. Christine's expert was able to cross-reference the pharmacy lien record with the neuropsychological test results, showing that medication escalations corresponded to periods of documented functional impairment, and that the ongoing regimen reflected the neuropsychologist's own assessment of incomplete recovery.

Future Medical Cost Foundation. The treating neurologist opined that Marcus would likely require ongoing cognitive support medication for at least 3-5 additional years, with uncertain longer-term prognosis. That opinion rested on the documented 18-month medication history showing no complete resolution.

[!KEY] Pharmacy records serve as the backbone for future medical cost projections in TBI cases. Without a continuous, documented medication history, a life care planner cannot credibly project ongoing pharmaceutical costs — and without those projections, the damages demand is incomplete.

Settlement Outcome

The case settled before trial for a seven-figure amount. The defense's position throughout litigation had been that Marcus's cognitive symptoms were pre-existing stress and burnout related to his business launch, and that the imaging findings were "minor." Christine's response was straightforward: a man who was not cognitively impaired before the crash does not require amantadine, methylphenidate, memantine, and sertraline for 15 months. The pharmacy record made that argument impossible to overcome.

The settlement included a life care plan component reflecting future medication management costs, consistent with the treating neurologist's projections.

Key Takeaways for Attorneys

TBI cases live or die on objective evidence. When a patient has no health insurance and is managing a complex, evolving cognitive medication protocol, a pharmacy lien program provides two things at once: the financial infrastructure to keep treatment going, and the documentation infrastructure to capture every clinical decision as it happens. Waiting until the end of a case to reconstruct the medication history from scattered pharmacy receipts is not a strategy — it is a gap that defense experts will exploit.

For cases involving moderate or severe TBI with cognitive medications, the pharmacy record is not supplemental evidence. It is central evidence.

Related Resources

• Concussion and TBI Medication Guide: Pharmacy Lien
• Gabapentin vs. Pregabalin for Personal Injury Nerve Pain
• What Is a Pharmacy Lien?
• How Long Will I Need Medications After an Accident?
• High-Value Personal Injury: Medication Strategy